Aduro Biotech Announces the Initiation of a Phase 1/2 Clinical Trial of BION-1301, a Novel Anti-APRIL Antibody, for the Treatment of Multiple Myeloma
Congratulations to Dr. Spira and his study team at the Research Institute for enrolling the first patient.
Data Presented Recently at ASH Demonstrate BION-1301’s Blocking of TACI in Addition to BCMA Results in Inhibition of Regulatory T Cells —
BERKELEY, Calif., Dec. 18, 2017 (GLOBE NEWSWIRE) — Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, today announced that the first patient in its Phase 1/2 dose escalation and dose expansion clinical trial (see www.clinicaltrials.gov, identifier NCT03340883) has been dosed at Virginia Cancer Specialists in Fairfax, Virginia, the first site in this multi-center trial. Read the complete Press Release Here
